Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 213

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 213
---
 between Yorkville and us,
(ii) the Oramed Note, (iii) the Tranche B Notes, (iv) the purchased revenue liability associated with the Purchase and Sale Agreement (the “ZTlido Royalty Purchase Agreement”) that we entered into in October 2024 with
certain institutional investors (collectively, the “ZTlido Royalty Investors”) and Oramed and (v) the purchased revenue liability associated with the Purchase and Sale Agreement (the “Gloperba-Elyxyb Royalty Purchase
Agreement”) that the we entered into in February 2025 with certain institutional investors (collectively, the “Gloperba-Elyxyb Royalty Investors”) and Oramed. See Note 4 titled “Fair Value Measurements” to our
consolidated financial statements appearing elsewhere in this prospectus.

Interest Expense, Net

Interest expense, net for the three months ended September 30, 2025 consists of interest on the balances due for government and commercial
rebate programs and interest related to the deferred consideration for GLOPERBA license acquired from Romeg in 2022. Government rebate programs include state Medicaid drug rebate programs and commercial rebate programs relate to contractual
agreements with commercial healthcare providers, under which we pay rebates for access to and position on that provider’s patient drug formulary. Interest expense, net for the three months ended September 30, 2024 consists of interest
related to the loans in an aggregate principal amount of up to $30.0 million (the “Revolving Facility”) made available by eCapital Healthcare Corp. pursuant to a Credit and Security Agreement (the “eCapital Credit
Agreement”) that Scilex Pharma entered into on June 27, 2023.

(Gain) Loss on Foreign Currency Exchange

(Gain) Loss on foreign currency exchange relates to foreign exchange (gain) loss on payments made to our foreign supplier, Itochu, a
manufacturer and supplier of lidocaine tape products, including ZTlido and SP-103.

137

Results of Operations The following tables summarize our results of operations for the three months ended September 30, 2025 and 2024 and the years ended December 31, 2024 and 2023 (in thousands):

|                                                        |     | 2025 | Three Months Ended September 30, |   |     | 2024 |         |   |     | Changes |          |   |     |